Wall Street analysts expect that Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) will post ($0.29) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Oramed Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.24) and the lowest estimate coming in at ($0.34). Oramed Pharmaceuticals reported earnings of ($0.18) per share in the same quarter last year, which suggests a negative year-over-year growth rate of 61.1%. The business is expected to report its next earnings report on Wednesday, November 27th.

According to Zacks, analysts expect that Oramed Pharmaceuticals will report full-year earnings of ($0.98) per share for the current year, with EPS estimates ranging from ($1.02) to ($0.92). For the next fiscal year, analysts anticipate that the firm will report earnings of ($0.99) per share, with EPS estimates ranging from ($1.00) to ($0.98). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that cover Oramed Pharmaceuticals.

Separately, HC Wainwright reiterated a “buy” rating on shares of Oramed Pharmaceuticals in a report on Wednesday, June 19th.

ORMP traded down $0.09 during trading on Friday, hitting $3.87. The stock had a trading volume of 46,245 shares, compared to its average volume of 33,690. Oramed Pharmaceuticals has a 12 month low of $2.78 and a 12 month high of $5.89. The company has a 50 day simple moving average of $3.42.

In other news, Director Leonard Sank bought 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 16th. The shares were purchased at an average price of $3.47 per share, for a total transaction of $69,400.00. Following the acquisition, the director now directly owns 315,482 shares of the company’s stock, valued at approximately $1,094,722.54. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders purchased a total of 25,817 shares of company stock worth $91,009 in the last quarter. Insiders own 27.70% of the company’s stock.

An institutional investor recently raised its position in Oramed Pharmaceuticals stock. BlackRock Inc. increased its position in Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) by 137.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 69,343 shares of the biotechnology company’s stock after acquiring an additional 40,114 shares during the period. BlackRock Inc. owned approximately 0.40% of Oramed Pharmaceuticals worth $208,000 as of its most recent SEC filing. 6.18% of the stock is currently owned by institutional investors.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule for the treatment of diabetes; and ORMD-0901, an oral glucagon-like peptide-1 analog capsule for the treatment of type 2 diabetes.

Featured Story: Short Selling Stocks, A Beginner’s Guide

Get a free copy of the Zacks research report on Oramed Pharmaceuticals (ORMP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Oramed Pharmaceuticals (NASDAQ:ORMP)

Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.